Skip navigation.

Lack of increased hepatotoxity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.

Publication year: 
Author (s): 
Ouyang, D W; Brogly, S B, Lu, M [et al.]
Publication details: 
Chicago, Wolters Kluwer Health, 2010
Publication in: 
AIDS. 2010 January 2; 24(1): pp.109–114

The objective of this study was to estimate whether HIV-infected pregnant women were at increased risk of hepatotoxicity when taking nevirapine (NVP) containing regimens compared to HIV-infected pregnant women taking antiretroviral therapy (ART) not containing NVP. Methods—This analysis included HIV-infected pregnant women on ART from two multicenter, prospective cohorts: The Women and Infants Transmission Study (WITS) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) protocol P1025. Multivariate Cox proportional hazards regression models were used to investigate the association between NVP use and hepatotoxicity. NVP use was dichotomized as use or no use and further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation(LEE) (grade 1-4) and severe LEE (grade 3-4). Results—A total of 1229 women with ART use during pregnancy were studied, 218 (17.7%) of whom received NVP. Among the women receiving NVP, 137 (62.8%) were NVP naïve. wentynine women (13.3%) who received NVP developed any LEE and one (0.5%) developed severe LEE. Of the 1011 women on non-NVP regimens, 145 (14.3%) developed any LEE and 14 (1.4%) developed severe LEE. There were no maternal deaths. In univariate models, LEE was not significantly associated with CD4+ count > 250 cells/μL or NVP use. In adjusted multivariate models, no significant increased risk of LEE (any or severe) in women taking NVP was detected
as compared to those taking other ART regardless of prior exposure history.